Journal
NATURE REVIEWS CANCER
Volume 15, Issue 1, Pages 55-64Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrc3844
Keywords
-
Categories
Funding
- European Research Council Advanced Researcher Award
- National Institute for Health Research (NIHR) Biomedical Research Centre, Cambridge, UK
- Cancer Research UK [10868] Funding Source: researchfish
Ask authors/readers for more resources
Since the Von Hippel-Lindau (VHL) disease tumour suppressor gene VHL was identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical and scientific interest. VHL tumour suppressor protein (pVHL) plays a key part in cellular oxygen sensing by targeting hypoxia-inducible factors for ubiquitylation and proteasomal degradation. Early inactivation of VHL is commonly seen in clear-cell renal cell carcinoma (ccRCC), and insights gained from the functional analysis of pVHL have provided the foundation for the routine treatment of advanced-stage ccRCC with novel targeted therapies. However, recent sequencing studies have identified additional driver genes that are involved in the pathogenesis of ccRCC. As our understanding of the importance of VHL matures, it is timely to review progress from its initial description to current knowledge of VHL biology, as well as future prospects for novel medical treatments for VHL disease and ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available